<DOC>
	<DOCNO>NCT03071692</DOCNO>
	<brief_summary>The primary objective study determine whether pemafibrate administer twice daily delay time first occurrence component clinical composite endpoint : - nonfatal Myocardial Infarction ( MI ) - nonfatal ischemic stroke - hospitalization unstable angina require unplanned coronary revascularization ; - Cardio Vascular ( CV ) death .</brief_summary>
	<brief_title>Pemafibrate Reduce Cardiovascular OutcoMes Reducing Triglycerides IN patiENts With diabeTes ( PROMINENT )</brief_title>
	<detailed_description>A multi-regional clinical trial participate site plan follow country pending approval applicable oversight authority : - Argentina - Brazil - Bulgaria - Canada - Colombia - Czech Republic - Denmark - France - Germany - Hungary - India - Israel - Japan - Mexico - Netherlands - Poland - Romania - Russian Federation - Slovakia - South Africa - Spain - Ukraine - United Kingdom - United States</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>1 . Fasting TG ≥ 200 mg/dL ( 2.26 mmol/L ) &lt; 500 mg/dL ( 5.65 mmol/L ) Visit 1 ( Screening/Enrollment Visit ) Visit 1.1 ( Retest ) 2 . HDLC ≤ 40 mg/dL ( 1.03 mmol/L ) Visit 1 ( Screening/Enrollment Visit ) Visit 1.1 ( Retest ) 3 . Type 2 diabetes longer 12 week duration document medical record , example : local laboratory evidence medical record review elevate HbA1c ( ≥ 6.5 % [ 48 mmol/mol ] ) , elevate plasma glucose ( fast ≥ 126 mg/dL [ 7.0 mmol/L ] , 2hour ≥ 200 mg/dL [ 11.1 mmol/L ] oral glucose tolerance testing , random value ≥ 200 mg/dL classic symptom , currently take medication treatment diabetes ; AND either 1 . Age ≥ 50 year male ≥ 55 year female ( primary prevention cohort ) ; OR 2 . Age ≥ 18 year establish systemic atherosclerosis ( secondary prevention cohort ) , define 1 following : . Prior MI ischemic ( nonhemorrhagic ) stroke ii . Coronary angiographic lesion ≥ 60 % stenosis major epicardial vessel ≥ 50 % leave main stenosis iii . Asymptomatic carotid disease ≥ 70 % carotid artery stenosis iv . Symptomatic carotid disease ≥ 50 % carotid artery stenosis v. Symptomatic low extremity PAD ( ie , intermittent claudication , rest pain , low extremity ischemic ulceration , major amputation either anklebrachial index ≤ 0.9 diagnostic test [ eg , toebrachial index , angiogram , image study ] ) vi . Prior arterial revascularization procedure ( include coronary , carotid , peripheral angioplasty/stenting , bypass , atherectomy/endarterectomy ) 1 . Current plan use fibrates agent PPARα agonist activity ( eg , saroglitazar ) within 6 week ( 42 day ) Visit 1 ( Screening/Enrollment Visit ) . Note : PPARγ agonist ( eg , glizatones pioglitazone rosiglitazone ) allow 2 . Known sensitivity PPARα agonists tablet excipients 3 . Initiation , change , current TGlowering therapy within 12 week Visit 1 ( applicable ) . Note : TGlowering therapy define niacin &gt; 100 mg/day dietary supplement prescription omega3 fatty acid &gt; 1 g/day 4 . Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>